The pharma industry continues to face significant challenges in formulating poorly water-soluble drugs, which constitute most new chemical entities.1
Integrating spray dried dispersions (SDD) — one of the most versatile and robust methods for preparing amorphous solid dispersion — with controlled release (CR) technologies offers a promising pathway to simultaneously address solubility limitations and the advantages of controlled release. The combination represents a powerful synergy in pharmaceutical development.
As more poorly soluble compounds enter the pipeline, formulators must consider both dissolution enhancement and tailored release kinetics to maximize therapeutic outcomes. Emerging trends, such as hybrid SDD-CR formulations for biologics and targeted delivery, suggest a growing role for this approach in future drug development. Pharma companies and CDMOs that invest in expertise across both SDD and CR technologies will be best positioned to develop next-generation therapeutics for challenging molecules.
Click here to read the full article.
This article was originally published in American Pharmaceutical Review, a CompareNetworks brand